Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score
Yushi Ueki, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii
Topics & Concepts
NivolumabMedicineInternal medicineHazard ratioHead and neck squamous-cell carcinomaOncologyCetuximabMultivariate analysisProportional hazards modelImmunotherapyHead and neck cancerRadiation therapyCancerConfidence intervalColorectal cancerHead and Neck Cancer StudiesCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis